Chemotherapy of hormone refractory prostate cancer

被引:1
|
作者
Wirth, MP [1 ]
Nippgen, J [1 ]
机构
[1] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Klin & Poliklin Urol, D-01307 Dresden, Germany
来源
UROLOGE A | 2003年 / 42卷 / 11期
关键词
hormone refractory prostate cancer; chemotherapy; estramustine; taxanes; mitoxantrone;
D O I
10.1007/s00120-003-0452-y
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
An increasing life expectancy and the growing number of largely healthy older men have lead to more patients with hormone insensitive relapses after palliative hormone or curative therapy for prostate cancer. After 10 years without therapeutic improvement for hormone refractory prostate cancer, the introduction of new substances has led to a revival of chemotherapy. Although a definitive cure is still not possible, such chemotherapy fulfils important palliative criteria-good toleration and an improvement in quality of life -in addition to distinct long-term remission. For example,taxane as a monotherapy or in combination with estramustine is effective and well tolerated while mitoxantrone in combination with prednisolone, although of limited effectiveness, leads to a substantial reduction in symptoms. Although evidence for increased longevity through modern chemotherapy is available,this has still not been definitively demonstrated. The substantial reduction in pain and therapy related morbidity frequently makes chemotherapy for hormone refractive prostate cancer a superior alternative to simple pain and complication management.
引用
收藏
页码:1453 / +
页数:6
相关论文
共 50 条
  • [1] Chemotherapy for hormone refractory prostate cancer
    Gridneva, Ya. V.
    Matveev, V. B.
    Bukharkin, B. V.
    Kupchan, D. Z.
    ONKOUROLOGIYA, 2010, 6 (04): : 54 - 60
  • [2] Chemotherapy for hormone refractory prostate cancer
    Smith, DC
    UROLOGIC CLINICS OF NORTH AMERICA, 1999, 26 (02) : 323 - +
  • [3] Chemotherapy in hormone-refractory prostate cancer
    de Wit, Ronald
    BJU INTERNATIONAL, 2008, 101 : 11 - 15
  • [4] Chemotherapy for advanced hormone refractory prostate cancer
    Petrylak, DP
    UROLOGY, 1999, 54 (6A) : 30 - 35
  • [5] Chemotherapy for hormone-refractory prostate cancer
    Shelley, Mike
    Harrison, Craig
    Coles, Bernadette
    Staffurth, John
    Wilt, Timothy J.
    Mason, Malcolm D.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (04):
  • [6] Chemotherapy of the hormone-refractory prostate cancer
    Heine, K
    Wolff, JM
    AKTUELLE UROLOGIE, 2004, 35 (03) : 209 - 214
  • [7] Chemotherapy in hormone-refractory prostate cancer
    Biedermann, B
    Pless, M
    Herrmann, R
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1999, 124 (28-29) : 874 - 879
  • [8] Chemotherapy in hormone-refractory prostate cancer
    Wolff, Johannes Maria
    CONTROVERSIES IN THE TREATMENT OF PROSTATE CANCER, 2008, 41 : 103 - 107
  • [9] Circulating chromogranin A and hormone refractory prostate cancer chemotherapy
    Cabrespine, A
    Guy, L
    Gachon, F
    Curé, H
    Chollet, P
    Bay, JO
    JOURNAL OF UROLOGY, 2006, 175 (04): : 1347 - 1352
  • [10] Metronomic chemotherapy for hormone refractory prostate cancer (HRPC)
    Hoshi, S.
    Numahata, K.
    Hoshi, K.
    Suzuki, K.
    Ono, K.
    Sugano, O.
    Ihidoya, S.
    Saito, S.
    Arai, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)